Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
Authors
Keywords
-
Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 190, Issue -, Pages 114525
Publisher
Elsevier BV
Online
2022-09-11
DOI
10.1016/j.addr.2022.114525
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634
- (2021) Florence Atrafi et al. Cancers
- Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach
- (2020) Yi-Hsien Cheng et al. ACS Nano
- Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis
- (2020) Hwaryeon Lee et al. Scientific Reports
- Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors
- (2020) Florence Atrafi et al. CLINICAL CANCER RESEARCH
- Past, Present, and Future of Anticancer Nanomedicine
- (2020) Kyungeun Kim et al. International Journal of Nanomedicine
- What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
- (2020) Duxin Sun et al. ACS Nano
- Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
- (2020) Johnique T. Atkins et al. BRITISH JOURNAL OF CANCER
- Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
- (2020) David A. Wheeler et al. CANCER CELL
- Enhancing anti-tumour efficacy with immunotherapy combinations
- (2020) Funda Meric-Bernstam et al. LANCET
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
- (2019) Yasuhiro Fujiwara et al. BRITISH JOURNAL OF CANCER
- Why maximum tolerated dose?
- (2019) Hans G. Stampfer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The beginning of the end of the nanomedicine hype
- (2019) Kinam Park JOURNAL OF CONTROLLED RELEASE
- NCI Centers of Cancer Nanotechnology Excellence (CCNEs) – A full story to set the record straight
- (2019) Piotr Grodzinski JOURNAL OF CONTROLLED RELEASE
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Nanomedicines Lost in Translation
- (2019) Keegan Guidolin et al. ACS Nano
- Nanomedicine researchers: Slow down to speed up
- (2019) Christine Allen JOURNAL OF CONTROLLED RELEASE
- Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small
- (2018) Puneet Tyagi et al. JOURNAL OF CONTROLLED RELEASE
- Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial
- (2018) Luca Gianni et al. JAMA Oncology
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
- (2018) Christopher B. Rodell et al. Nature Biomedical Engineering
- Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)
- (2018) Bei Xu et al. MEDICINE
- Polymer–drug conjugate therapeutics: advances, insights and prospects
- (2018) Iriny Ekladious et al. NATURE REVIEWS DRUG DISCOVERY
- Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients
- (2017) Clarissa Ruggeri et al. HEART FAILURE REVIEWS
- The drug delivery field needs a well-diversified technology portfolio
- (2017) Kinam Park JOURNAL OF CONTROLLED RELEASE
- Watching the gorilla and questioning delivery dogma
- (2017) Thomas J. Anchordoquy et al. JOURNAL OF CONTROLLED RELEASE
- Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection
- (2017) Az Alddien Natfji et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
- (2017) In Hae Park et al. Cancer Research and Treatment
- Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
- (2017) FNU Asad ur Rahman et al. Therapeutic Advances in Gastroenterology
- Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
- (2016) N V Rajeshkumar et al. BRITISH JOURNAL OF CANCER
- Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma
- (2016) Michael A. Fridrik et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin
- (2016) Grant H. Petersen et al. JOURNAL OF CONTROLLED RELEASE
- Drug delivery of the future: Chasing the invisible gorilla
- (2016) Kinam Park JOURNAL OF CONTROLLED RELEASE
- To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
- (2016) F. Danhier JOURNAL OF CONTROLLED RELEASE
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
- (2016) Michael Untch et al. LANCET ONCOLOGY
- Nanomedicines for renal disease: current status and future applications
- (2016) Nazila Kamaly et al. Nature Reviews Nephrology
- Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
- (2016) Daniel Bobo et al. PHARMACEUTICAL RESEARCH
- CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
- (2016) Andrew J. Clark et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of nanoparticle delivery to tumours
- (2016) Stefan Wilhelm et al. Nature Reviews Materials
- Recommendations for Benchmarking Preclinical Studies of Nanomedicines
- (2015) C. M. Dawidczyk et al. CANCER RESEARCH
- Clinical Translation of Nanomedicine
- (2015) Yuanzeng Min et al. CHEMICAL REVIEWS
- Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
- (2015) M. H. Kang et al. CLINICAL CANCER RESEARCH
- Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses
- (2015) Gideon M. Blumenthal et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
- (2015) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
- (2015) Bonnie Huang et al. Science Translational Medicine
- A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
- (2014) A. Awada et al. ANNALS OF ONCOLOGY
- Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
- (2014) A. V. Kalra et al. CANCER RESEARCH
- Translation from mouse to human: Time to think in new boxes
- (2014) Kinam Park JOURNAL OF CONTROLLED RELEASE
- EPR: Evidence and fallacy
- (2014) Joseph W. Nichols et al. JOURNAL OF CONTROLLED RELEASE
- Just so stories: The random acts of anti-cancer nanomedicine performance
- (2014) Seyed Moein Moghimi et al. Nanomedicine-Nanotechnology Biology and Medicine
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma†
- (2013) A. C. Roy et al. ANNALS OF ONCOLOGY
- The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer
- (2013) W. W. Ma et al. CLINICAL CANCER RESEARCH
- Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice
- (2013) Darren Lars Stirland et al. JOURNAL OF CONTROLLED RELEASE
- nab-Paclitaxel mechanisms of action and delivery
- (2013) Denise A. Yardley JOURNAL OF CONTROLLED RELEASE
- Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: Lessons learned of the EPR effect and image-guided drug delivery
- (2013) Christin P. Hollis et al. JOURNAL OF CONTROLLED RELEASE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generation of Effector Memory T Cell-Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination
- (2013) A. V. Li et al. Science Translational Medicine
- Liposomal drug delivery systems: From concept to clinical applications
- (2012) Theresa M. Allen et al. ADVANCED DRUG DELIVERY REVIEWS
- First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
- (2012) Ó Arrieta et al. BRITISH JOURNAL OF CANCER
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- (2012) Yechezkel (Chezy) Barenholz JOURNAL OF CONTROLLED RELEASE
- Mifamurtide for the treatment of nonmetastatic osteosarcoma
- (2011) Kosei Ando et al. EXPERT OPINION ON PHARMACOTHERAPY
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
- (2011) Heikki Joensuu et al. LANCET ONCOLOGY
- Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
- (2011) Yutaka Yamamoto et al. OncoTargets and Therapy
- Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
- (2010) G. P. Stathopoulos et al. ANNALS OF ONCOLOGY
- HPMA copolymers: Origins, early developments, present, and future☆
- (2009) Jindřich Kopeček et al. ADVANCED DRUG DELIVERY REVIEWS
- Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities☆
- (2009) Ruth Duncan et al. ADVANCED DRUG DELIVERY REVIEWS
- Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer
- (2009) Zhong-Zhen GUAN et al. Asia-Pacific Journal of Clinical Oncology
- 9088 Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis
- (2009) C. Kosmas et al. EJC SUPPLEMENTS
- Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
- (2009) Teni Boulikas EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
- (2009) Seymour INTERNATIONAL JOURNAL OF ONCOLOGY
- Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
- (2009) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer
- (2009) N. Mylonakis et al. LUNG CANCER
- Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study
- (2008) Luís A. Pires et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pegylated Liposomal Doxorubicin
- (2008) Greg L Plosker DRUGS
- Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
- (2008) Paul A. Meyers et al. JOURNAL OF CLINICAL ONCOLOGY
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started